FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer by Stehbens, Samantha J. et al.
RESEARCH ARTICLE
FGFR2-activating mutations disrupt cell polarity to potentiate
migration and invasion in endometrial cancer cell models
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ABSTRACT
Fibroblast growth factor receptors (FGFRs) are a family of receptor
tyrosine kinases that control a diverse range of biological processes
during development and in adult tissues. We recently reported that
somatic FGFR2 mutations are associated with shorter survival in
endometrial cancer. However, little is known about how these FGFR2
mutations contribute to endometrial cancer metastasis. Here, we
report that expression of the activating mutations FGFR2N550K and
FGFR2Y376C in an endometrial cancer cell model induce Golgi
fragmentation, and loss of polarity and directional migration. In mutant
FGFR2-expressing cells, this was associated with an inability to
polarise intracellular pools of FGFR2 towards the front of migrating
cells. Such polarization defects were exacerbated in three-
dimensional culture, where FGFR2 mutant cells were unable to
form well-organised acini, instead undergoing exogenous ligand-
independent invasion. Our findings uncover collective cell polarity
and invasion as common targets of disease-associated FGFR2
mutations that lead to poor outcome in endometrial cancer patients.
KEY WORDS: FGFR, Endometrial cancer, Invasion, Migration,
Polarity
INTRODUCTION
Fibroblast growth factor receptors (FGFRs) 1–4 are receptor tyrosine
kinases (RTKs) (Baird et al., 1986; Turner and Grose, 2010). FGFR
signalling plays a key role in mammalian embryogenesis,
development and tissue homeostasis. Dysregulation of FGFR
expression and signalling that can occur through genomic
alterations are associated with pathological disease states, such as
cancer (Babina and Turner, 2017; Dienstmann et al., 2014). Multiple
members of this family are currently being pursued as cancer
therapeutic targets.
We previously identified FGFR2-activating mutations in
endometrial cancer (Pollock et al., 2007) that are associated with
an increased risk of recurrence in a single institutional cohort (Byron
et al., 2012). Confirmatory studies in a multi-institutional cohort of
over 950 endometrial cancer patients now show that FGFR2
mutations are associated with a decreased disease-free survival and
decreased endometrial cancer-specific survival (Jeske et al., 2017).
Endometrial cancer is the most common gynecologic malignancy in
developed countries (SGO Clinical Practice Endometrial Cancer
Working Group et al., 2014) with ∼76,000 deaths per year
worldwide (Ferlay et al., 2015). Although 75% of endometrial
cancers are detected early and have a good prognosis, patients who
relapse post resection or present with metastatic disease have a very
poor prognosis with a median survival of 7–12 months (Creutzberg
et al., 2000). There is currently no treatment to cure patients with
metastatic disease, highlighting the urgent need for new therapies
(Longoria and Eskander, 2015; Temkin and Fleming, 2009). The
majority of endometrial cancer-associated FGFR2 mutations are
identical to germline activating mutations that result in
developmental syndromes (Pollock et al., 2007). How these
FGFR2 mutations function in the context of cancer is unknown.
Here, we define the molecular mechanisms of two of the activating
mutations we previously identified to be associated with recurrent
disease and decreased survival, FGFR2N550K and FGFR2Y376C.
All members of the FGFR family have a ligand-binding
extracellular domain and a transmembrane domain, followed by a
cytoplasmic kinase domain (Olsen et al., 2004). FGFR1–FGFR3
can undergo alternative splicing in the ligand-binding domain to
give rise to alternative ‘b’ and ‘c’ isoforms that possess different
ligand-binding specificities (Mohammadi et al., 2005; Ornitz and
Itoh, 2001). For FGFR2, cells of an epithelial lineage typically
express the ‘b’ isoformwhich binds FGF1, FGF3, FGF7, FGF10 and
FGF22, ligands normally expressed by the underlyingmesenchyme.
Conversely, stroma typically expresses the alternative ‘c’ isoform,
which responds to epithelium-derived FGF ligands. Consequently,
this means that the local environment or stroma can signal to the
adjacent epithelial structures and vice versa, a relationship that is
often perturbed in invasive cancer (Dienstmann et al., 2014).
Classically, ligand-activated FGFR2 signals through signalling
pathways including Ras–MAPK, PI3K–Akt, PLCγ, STAT and Src
(Turner and Grose, 2010; Ornitz and Itoh, 2015), although the
relative contribution of each pathway differs in different tissue
contexts. The dogma for RTK signalling is that following activation,
plasma membrane RTKs undergo receptor-mediated-endocytosis as
a means of terminating cell surface signalling. However, it is now
clear that receptors can continue to signal from endosomes
following internalization (Jean et al., 2010; Villaseñor et al.,
2016), enabling spatiotemporal signalling required for complex
cellular functions such as cell migration. Previous studies of
germline FGFR mutations indicate that point mutations in the
receptor can result in differential localization and signalling (Citores
et al., 2007; Harada et al., 2007; Lievens et al., 2004, 2006; Ahmed
et al., 2008; Hatch et al., 2006). The mechanisms by which FGFR2Received 4 December 2017; Accepted 24 June 2018
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mutations initiate and/or drive endometrial cancer tumorigenesis
and contribute to poor patient outcomes has not yet been identified.
In an effort to elucidate the biological consequence of FGFR2-
activating mutations in endometrial cancer, we have established
Ishikawa endometrial cancer cells expressing low levels of C-
terminal eGFP-tagged wild-type (WT) and mutant FGFR2 (the
epithelial ‘b’ isoform, hereafter referred to as FGFR2), FGFR2N550K
and FGFR2Y376C, hereafter referred to as N550K and Y376C. Our
rationale for studying these two activating mutations was two-fold;
in comparison to the ligand-promiscuous mutation S252W, they are
relatively understudied and although they are both considered to be
activating mutations, this occurs through differing mechanisms.
N550K, the second-most common FGFR2 mutation in endometrial
cancer (Pollock et al., 2007), occurs in the kinase domain and is a key
residue that forms part of the molecular brake region, which
functions to restrict a conformational change to the active state (Chen
et al., 2007; Byron et al., 2013). Y376C is a poorly characterised
extracellular juxta-membrane mutation that introduces an extra
cysteine residue that has been shown to facilitate disulfide-mediated
receptor dimerization and activation in FGFR2 and FGFR3
(Adar et al., 2002; Byron et al., 2010; Robertson et al., 1998).
We report that expression of the activating mutations perturb
polarization,migration and three-dimensional (3D) organization into
acinar structures, ultimately leading to invasion.Mechanistically, we
observe Golgi fragmentation and an inability of cells to reorient their
intracellular pools of FGFR towards the leading edge, concomitant
with a loss of directional migration during ligand-induced
chemotaxis and chemokinesis. In a 3D acinus model, we observe
an exogenous ligand-independent disruption of polarity concomitant
with cells undergoing invasion into the extracellular matrix (ECM),
which can be further potentiated by ligand (FGF10). Our findings
suggest that the common target of FGFR-activating mutations in
endometrial cancer is to disrupt the coordination of multicellular
polarity, thereby priming cells for invasion. This study sheds light on
the association of FGFR2 mutations with increased metastatic risk.
RESULTS
FGFR2-activating mutations exhibit aberrant receptor
localization and signalling
To determine how FGFR2 activating mutations affect receptor
function, we examined the spatio-temporal dynamics of eGFP-
tagged WT FGFR2 and two activating mutations, N550K and
Y376C, in Ishikawa endometrial cancer cells. To ensure there was
no interference of C-terminal-binding partners, we included a linker
region between the tag and the FGFR C-terminus (Mohammadi
et al., 1991; Timsah et al., 2014; Lin et al., 2012). Ishikawa cells are
a representative model of well-differentiated endometrial cancer;
they express low levels of FGFR2, allowing us to examine the
contribution of exogenous mutant expression, and show constitutive
PI3K pathway activation due to a loss-of-function PTEN mutation.
This genetic background makes them clinically relevant as most
endometrial cancers with FGFR2 activation also carry loss-of-
function PTEN mutations (Byron et al., 2008). As N550K occurs in
the kinase domain and Y376C is an extracellular juxta-membrane,
dimerizing mutation (Byron et al., 2010) (Fig. 1H; Fig. S1F), we
hypothesized that, owing to potential conformational changes, their
receptor spatio-temporal localization dynamics may differ, resulting
in differential downstream signalling and cellular functions.
To ascertain whether the activating mutants localized
differentially to WT protein, we examined receptor expression by
live-cell spinning disc confocal (SDC) microscopy. In normal
growth conditions (10% serum), WT FGFR2 localized to the cell
membrane, as evidenced by an opaque surface fluorescence
(Fig. 1A), in addition to a highly dynamic intracellular vesicular
population (Movie 1). In contrast, both activating mutations had a
pronounced intracellular pool (Fig. 1A and Fig. S1A) and led to an
increase in the size of vesicular structures (Fig. 1B; mean size: WT,
0.42 µm2; N550K, 0.62 µm2; Y376C, 0.52 µm2), with an increased
number of vesicles also present in N550K cells (Fig. 1B; mean
number: WT, 107; N550K, 165; Y376C, 133). These observations
were supported by X-T kymographic analysis whereby diagonal
tracks and vertical lines are indicative of dynamic and stationary
vesicles, respectively (Fig. 1C). TheWT receptor vesicles weremore
dynamic in contrast to the activating mutations, which was reflected
in the quantitative analysis of vesicle trajectories over time (Fig. 1D).
Membrane localization of activating mutant receptors was notably
less in comparison to WT (Fig. 1A). To confirm the enhanced
intracellular localization of mutant FGFR2, we next performed total
internal reflection (TIRF) microscopy, which selectively illuminates
proteins situated in close proximity to the plasma membrane (within
∼100 nm) (Mattheyses et al., 2010) (Fig. 1E). Mutant FGFR2 was
notably less at the cell surface in comparison to WT, which was
confirmed by quantification of WT and mutant receptor integrated
fluorescence intensity [Fig. 1F; mean TIRF fluorescence intensity in
arbitrary units (a.u.): WT, 5859; N550K, 3099; Y376C, 2695]. We
further supported the TIRF imaging approach, measuring surface
receptor levels by selective-surface receptor labelling using an anti-
FGFR2 antibody targeted to an N-terminal epitope in non-
permeabilized conditions (Fig. S1B; ratio of surface to total mean:
WT, 0.40; N550K, 0.31, Y376C, 0.23). These observations were
also supported by cell surface biotinylation experiments on cells
grown in 10% FBS. FGFR2 expression was assessed via western
blotting of lysates generated by subcellular cell lysate fractionation
and immunoprecipitation with streptavidin beads (Fig. S1C). A long
exposure showed membrane localization of biotin-labelled WT
FGFR2 but not mutant FGFR2 (boxed regions). These data suggest
that in cells in serum, less mutant FGFR is present at the surface and
it is predominantly intracellular.
We next examined whether FGFR activating mutants
differentially regulated classical signalling pathways downstream
of the receptor. We confirmed the exogenous expression levels of
eGFP-tagged WT and mutant receptors by western blotting with
antibodies against both the C- and N-terminal FGFR2 in addition to
eGFP immunoblotting (Fig. 1G; Fig. S1D). A lower ∼75 kDa band
representing a cleaved form of FGFR2 was evident with a C-
terminal antibody (C-17) as well as an antibody targeting eGFP
(Fig. 1G). Endogenous levels of FGFR2 are low in the parental
Ishikawa cell line and are almost undetectable in western blotting
and immunofluorescence experiments allowing us to express
FGFR–eGFP WT and mutations to levels observed in endometrial
cancer cell lines that endogenously overexpress mutant FGFR2
(Taurin et al., 2018). Western blot analysis of cells grown in 10%
serum revealed that expression of activating mutants resulted in a
differential activation of downstream FGFR signalling pathways
(Fig. 1G; Fig. S1D,E). Notably, expression of the N550K mutant
resulted in increased phosphorylation of FGFR2, the FGFR-
interacting protein FRS2α (at T436) and PLCγ-1 (at T783)
(subunit encoded by PLCG1) in comparison to WT and Y376C,
although PLCγ (T783) phosphorylation was also elevated for this
latter mutant compared to WT. This indicates that although both
mutants are activating, they may differ in their engagement of
adaptor molecules and activation of downstream effectors.
Together, with the live-cell imaging results, these data suggest
that signalling may occur from intracellular compartments.
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Ligand-dependent signalling differs in intensity and duration
in FGFR-activating mutants
In order to investigate ligand-dependent signalling downstream of
the activating mutants, we assessed whether mutant receptors could
be recruited to the cell surface when deprived of serum. We
observed a progressive loss of the intracellular pool of the receptors
in all cells during live-cell imaging of serum starvation, suggesting
receptors were being recruited to the plasma membrane (Fig. S2A),
Fig. 1. FGFR2 mutations result in aberrant receptor localization and signalling. (A) Live-cell spinning disc confocal microscopy of Ishikawa cells stably
expressing eGFP-tagged FGFR2 WT, Y376C or N550K. In this and subsequent figures, images are contrast inverted to better visualize receptor localization.
(B) Analysis of average vesicle size and number, per cell (n). n=23 (WT), 20 (N550K), 20 (Y376C). Box-and-whisker plots show median, first and third
quartile (box), and 95% confidence intervals (notches) with whiskers extending to the furthest observations within ±1.5 times the interquartile range. Dots are
individual data points.P-values were calculated by a non-parametric Kruskal–Wallis analysis of variancewith Dunn’smultiple comparisons test correction and are
displayed on graph. (C) Maximum intensity projection of x-t (time) kymographs of intracellular FGFR2 vesicular structures from cells in A. Static or pausing
vesicles create vertical lines, dynamic vesicles create diagonal lines. Arrowheads identify a single vesicle track in each kymograph. (D) Averaged mean squared
displacement plots of WT and mutant vesicle trajectories, as a function of time. (E) Representative TIRF microscopy images of WT and mutant FGFR-expressing
cells. Excitation was at 488 nm. (F) Quantification of TIRF 488 nm fluorescence intensity, indicating that the mutant eGFP–FGFR2 variants have lower levels at
the cell surface in comparison to WT. (G) Immunoblot of FGFR2 WT and N550K, Y376C mutant cell lines in normal growth conditions (10% FBS) probed for
FGFR2 and proteins indicative of activated signalling pathways. Tubulin was used as a loading control. (H) Schematic of the FGFR2b surface dimer with the
positions of mutations indicated. A detailed statistical summary for this and subsequent figures can be located in Table S2.
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which was supported by cell surface biotinylation experiments
(Fig. S2B). We readily observed cell surface recruitment with
comparable membrane levels of WT and mutant FGFR2 in serum-
starved conditions. We confirmed receptor surface recruitment
by SDC time-lapse microscopy, where we analysed receptor
internalization dynamics by stimulating serum-starved cells with
FGF10 ligand (50 ng/ml), including heparin sulfate (5 µg/ml) to
facilitate ligand binding and receptor dimerization. In WT cells, the
opaque surface signal decreased over time (Fig. 2A), correlating
with the appearance of vesicular structures (Fig. 2B), which
coalesced towards the perinuclear receptor pool, becoming more
predominant (Fig. 2C) as the surface receptor levels decreased. We
observed similar phenomena in cells expressing mutant receptor,
although the localization of the internalized receptor to the
perinuclear pool and decreased rate of surface internalization was
not as pronounced (Fig. S2C). These observations were supported
by quantification of mutant receptor localization dynamics
(Fig. 2D). These data suggest that the N550K and Y376C
mutants can be recruited to the surface when serum deprived, and
they exhibit differential receptor internalization dynamics when
stimulated with ligand.
We next examined whether the differences in receptor
internalization dynamics were reflected in FGFR2-dependent
signalling pathways in response to ligand (Fig. 2E; 50 ng/ml
FGF10, 5 µg/ml heparin sulfate, 0.5% FBS). Activation of FRS2α
and PLCγ-1 by FGF10 was evident in WT transduced cells but not
cells transduced with empty vector, confirming the phenotypic and
signalling changes observed were mediated by exogenous FGFR2.
Most notably, we observed alterations in the PLCγ pathway in cells
expressing both mutants in comparison to WT. In N550K-
expressing cells, we observed both a stronger and earlier
induction of PLCγ-1T783 phosphorylation than in WT (Fig. 2E,F).
In comparison, in Y376C-expressing cells the addition of
FGF10 resulted in modest, but stable, induction of PLCγ-1T783
phosphorylation. Ishikawa cells do not possess mutations in any
RAS family member (Weigelt et al., 2013), but do show constitutive
activation of the MAPK pathway through an unidentified
mechanism in serum-starved conditions (Fig. 2E, 0 min).
Although ERK1 and ERK2 (ERK1/2, also known as MAPK3 and
MAPK1, respectively) shows constitutive activation in cells
transduced with empty vector (EV)-GFP, a further increase in
ERK1/2 phosphorylation was seen following the addition of FGF10
in cells transduced withWT, and this increased phosphorylation was
sustained over a longer period of time in cells expressing the
activating mutations.
To investigate the phenotypic output of signalling downstream of
the activating mutations, we measured cell proliferation using total
protein levels in combination with live-cell microscopy studies.
Expression of the activating mutations resulted in an increase in
proliferation, independent of ligand (Fig. 2G). Unexpectedly, the
addition of ligand to WT-, N550K- or Y376C-expressing cells
resulted in decreased proliferation. To further clarify this effect, we
examined the cells by live-cell imaging over 6 days (Movie 2). In
WT cells, we observed an induction of cell migration with the
addition of ligand, with cells losing their epithelial cobblestone
appearance, moving away from cell islands to move as single cells.
In cells expressing N550K, this migratory phenotype was present in
unstimulated conditions and slightly enhanced with ligand. In
contrast, in cells expressing Y376C, we observed two populations,
one with an enhanced migration of individual cells and another with
an aberrant growth pattern whereby cells grew in tightly clustered
islands. This suggests that stimulation of FGFR-dependent
signalling induces a switch from proliferation to a pro-migratory
phenotype in endometrial cancer.
FGFR-activating mutants are not sequestered in the
endoplasmic reticulum
Previous studies of dimerizing mutants in other FGFR family
members have reported that mutant receptors are retained in the
endoplasmic reticulum (ER) or Golgi en route to the cell surface
(Hatch et al., 2006) (reviewed in Foldynova-Trantirkova et al.,
2012). To test whether the enriched receptor endosomal pool was
due to Golgi retention, we examined the localization of eGFP-
tagged receptors relative to the Golgi marker GM130 (also known as
GOLGA2) through immunofluorescence in full growth medium
(10% FBS). Whereas the perinuclear pool of receptors localized in
close proximity to the Golgi (Fig. 3A), there was limited overlap,
indicating that the receptor was unlikely to be sequestered in the
Golgi. Interestingly, we observed fragmentation of the Golgi in cells
expressing activating mutants. As the fixation required for
immunofluorescence destroys the ER reticular structure and
potentially the antigen epitope, resulting in diffuse ER/calnexin
staining (Melan and Sluder, 1992; Schnell et al., 2012;
Bhattacharyya et al., 2010) (Fig. S3A), we visualized the ER
through live imaging of cells co-expressing the ER marker
mCherry–Sec61. We observed vesicular FGFR2 directly adjacent
to mCherry-Sec61 reticular structures, which extended to the cell
periphery (Fig. 3B,C). To explore both of these observations further
we examined mutant receptor spatio-temporal dynamics in cells co-
expressing a mCherry-labelled marker for the Golgi (Rab6a;
Fig. 3D,E, Movie 3) and ER (Sec61; Fig. 3B,C, Movie 4) using
live-cell SDC microscopy. Vesicular FGFR2 structures of both WT
and mutant FGFR2 moved unhindered, independently of any
obvious retention in either Golgi or ER structures. This indicates
that FGFR2-activating mutants are not retained in the ER or Golgi.
In order to identify the intracellular compartment that receptors were
localizing to, we examined a panel of classic endosomal and
lysosomal compartment markers by immunofluorescence,
including those for recycling endosomes (Rab11), the ER-Golgi
compartment (ERGIC53, also known as LMAN1), lysosomal
markers (Lamp1, Lysotracker) and markers for late endosomes
(Rab7). Surprisingly, we observed no apparent differential
endosomal localization of either of the FGFR mutants in
comparison to WT receptors (Fig. S3B–F). Although the caveat
remains that mutant FGFRs may localise to an unidentified
endosomal pool, our data suggest that the differential signalling
we observe is not due to altered trafficking routes of the FGFR
mutants per se, but rather is due to enhanced localization to the
classical endocytic route for FGFR2 combined with constitutively
active receptor signalling from these compartments. This concept is
similar to activating mutants reported for the HGF receptor c-Met
(Ménard et al., 2014; Barrow-McGee and Kermorgant, 2014).
Expression of FGFR-activating mutants results in
fragmentation of the Golgi apparatus
As Golgi integrity and polarization towards the leading edge of cells
is typically involved in persistent migration in one direction
(‘productive migration’) (Kupfer et al., 1987; Etienne-Manneville,
2004; Miller et al., 2009), we next addressed the role of Golgi
organization in mutant-expressing cells. Expression of activating
mutants resulted in a ∼30–50% increase in the angle (Fig. 4A,B;
mean: N550K, 147°; Y376C, 172°) of Golgi dispersion in
comparison to WT (116°). To test for the impact of these changes
on migration, we imaged cells expressing WT or mutant receptors
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Fig. 2. See next page for legend.
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by time-lapse epifluorescence microscopy during wound closure
in the presence and absence of FGF10 ligand stimulation. We
co-expressed mCherry empty vector in all conditions to generate
high-contrast images to facilitate cell tracking. We observed that
cells expressing WT FGFR2 were able to close the wound within
24 h, with leading edge cells moving in a coordinated manner
(Fig. 4C–E). In contrast, cells expressing activating mutations
exhibited erratic migration dynamics, with cells often breaking free
from the leading edge and individually migrating in and out of the
wound, resulting in failure to close the wound (Movie 5). This
suggested that the perturbation of Golgi polarization observed in
activating mutants resulted in the loss of polarized migration.
FGFR-activating mutants exhibit a loss of directional
persistence during two-dimensional migration
As our data indicate that FGFR2-activating mutations induce a
migration polarization defect, we examined the ability of cells to
respond to an FGF chemotactic gradient (Fig. 5A). We quantified
four migration parameters to describe migration behaviour: total
track length; displacement, the shortest distance between the initial
and final points; persistence, a ratio of cell displacement to distance
migrated and speed (see the Materials and Methods for formula
details). In the absence of ligand, WT and N550K cells exhibited
limited intrinsic migration, often oscillating in place. In contrast,
Y376C cells showed significantly longer total track lengths,
displacement and speed supporting the constitutive activation of
this mutant receptor (Fig. 5B–E). In the presence of a FGF10
gradient, WT cells migrated persistently towards the gradient, a
behaviour not observed in cells expressing mutant FGFR2. Instead,
mutant cells exhibited an increase in tortuosity, randomly switching
direction throughout the time-lapse sequence, seemingly unable to
detect the ligand-gradient, an observation that was substantiated by
migration track plots and the loss of directionality (Fig. 5A,D;
persistence). In WT cells, the increase in track length observed with
the addition of ligand correlated with an increase in migration speed
and productive migration towards the ligand gradient. The increase
in migration in response to ligand observed in the cells expressing
WT receptor was not seen in cells expressing mutant receptor. We
observed similar findings in chemokinesis assays (Fig. S4).
Collectively, our data demonstrate that the fragmented Golgi
observed in mutant cells is concomitant with a strong defect in
polarity and directional migration.
To elucidate how the migration phenotype of mutant cells
resulted in non-productive migration, we examined cells co-
expressing the filamentous actin reporter mCherry–Lifeact by
time-lapse SDCmicroscopy (Riedl et al., 2008) (Movie 6). Live-cell
imaging revealed that WT cells stimulated with FGF10 were able to
undergo polarized migration, forming a broad fan-like, leading-
edge lamellipodia with a trailing rear (Fig. 5F). N550K mutant cells
appeared unable to polarize and instead extended and retracted
multiple lamellipodial extensions in a seemingly random manner
(Fig. 5G,H).
As (1) mutant FGFRs were predominantly intracellular in serum-
containing conditions (Fig. 1), and (2) these could be recruited to
the PM upon serum withdrawal (Fig. 2), and (3) that the Golgi and
MTOC orient towards chemotactic gradients, we reasoned that the
intracellular pools of FGFR2may similarly need to polarize towards
the leading edge of cells. To this end, we observed that the
perinuclear pool of receptor oriented towards the migrating front of
WT cells. In stark contrast, mutant cells exhibited a dispersed
perinuclear receptor pool with no clear orientation (Fig. 5F,G;
Movie 7). Taken together, this demonstrates that activating
mutations in FGFR2 result in a loss of front–rear polarity,
concomitant with an inability to organize the endosomal pool of
FGFR, and a decrease in polarized migration in both 2D
chemotactic and chemokinesis assays.
FGFR-activating mutations differentially effect endometrial
acinar morphogenesis and 3D invasive migration
A common feature of tumorigenesis is the progressive loss of tissue
architecture (Halaoui et al., 2017), which in healthy tissue requires
the collective coordination of individual polarity of each cell. We
reasoned that mutant FGFRs should therefore display a defect in
multicellular polarization. We generated acini expressing WT and
activating mutants of FGFR by adapting the well-established
Matrigel™ overlay assay (Bryant and Mostov, 2008; Debnath and
Brugge, 2005; Lee et al., 2007). In brief, acini were grown for 8 days
from a single-cell that proliferates and assembles into a polarized
spherical monolayer with a central lumen, a structure that is dictated
by a compliant ECM (Matrigel™). Empty vector control and WT
receptor-expressing acini formed well-polarized structures with the
Golgi oriented towards the apical lumen and the basement
membrane marker β4-integrin (ITGB4) demarcating the basal
Fig. 2. Ligand-dependent internalization and signalling of FGFR2WT and
activating mutants in Ishikawa cells. (A) Spinning disc confocal microscopy
of eGFP-tagged FGFR2 WT receptor internalization dynamics in response to
FGF10 ligand stimulation. Ishikawa cell stably expressing eGFP-labelled WT
FGFR2 receptor (cyan) that were serum starved (90 min; 0.5% FBS, t0), prior
to the addition of ligand (50 ng/ml FGF10, 5 µg/ml heparin). The ROI1 (yellow)
indicates the area for the total or surface receptor, the ROI2 (white) indicates
the area of the perinuclear receptor pool. Time is in minutes. (B) Time-lapse
images of outlined boxed area in A demonstrating receptor internalization as
visualized by a loss of opaque surface fluorescence, and an increase in
vesicular structures which coalesce and accumulate in the perinuclear pool.
(C) Time-lapse images of perinuclear receptor accumulation from A,
demonstrating an increase in receptor fluorescence intensity over time.
Intensity values are inverted and image is scaled to 50% for display purposes
to prevent saturation of vesicular structures. Hoechst 33342 (magenta) labels
the nucleus in A–C. (D) Quantification of receptor internalization dynamics of
eGFP-labelled WT and mutant FGFR2. Fluorescence intensity profiles
measured as a function of timewere normalized to the t0 intensity for each ROI
outlined in A (n≥10 cells per condition). The solid line is the average intensity of
all ROIs and dashed lines are 95% confidence intervals. The surface receptor
fluorescence decreases in response to ligand (ROI1, blue line), whereas the
perinuclear receptor fluorescence (ROI2, grey line) intensity plots exhibit
variable dynamics over time in response to ligand. (E) Immunoblots of
Ishikawa cells stably overexpressing eGFP-tagged FGFR2 WT and activating
mutants N550K and Y376C stimulated with FGF10. In brief, cells were serum
starved (0.5% FBS) overnight prior to ligand stimulation (50 ng/ml FGF10,
5 µg/ml heparin). At the indicated time points (0–16 h), cells were lysed and
collected for western blot analysis. Specific antibodies detecting total and
phosphorylated proteins that are indicative of activated downstream signalling
pathways were used. Tubulin was used as a loading control. The blot
presented is a representative example of three independent experiments.
(F) Quantification of PLCγ and FRS2α signalling from three independent
experiments. The signal for phosphorylated protein was divided by the signal
for total protein for PLCγ and FRS2α, and normalized to the value for the
loading control protein (α-tubulin). Time course values were normalized to t0
(starved) values. Error bars are s.d. (G) Quantification of cell proliferation as
measured by the whole-protein content fold increase (day 4 to day 0),
normalized to that in empty vector control cells. Cells were grown in 2% FBS
with 5 µg/ml heparin in the presence or absence of FGF10 (50 ng/ml); n=3
technical triplicates performed on two independent occasions. Graph is
mean±s.d. Representative frames from phase contrast time-lapse imaging of
Ishikawa cells stably expressing FGFR2 WT or N550K and Y376C, grown for
6 days are shown underneath. Cells were grown in 2% FBS with 5 µg/ml
heparin in the presence or absence of FGF10 (50 ng/ml). Scale bar: 20 µm.
Cells are colour highlighted to allow visualization of the cell morphology.
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Fig. 3. FGFR mutants are not sequestered in the Golgi or ER. (A) Representative images of eGFP-tagged cells expressing FGFR WT, N550K and Y376C
(green) fixed and stained for GM130 (magenta) to identify the Golgi, and DAPI (blue) as a nuclear stain. Insets indicate the close proximity of FGFR to Golgi
structures (white arrowheads). Single channels from boxed regions in the merged image are displayed with inverted contrast. The Golgi is outlined in control
cells with a dottedmagenta line. TheGolgi is fragmented inmutant-expressing cells. Scale bar: 20 µm. (B) Live-cell spinning disc confocal microscopy of Ishikawa
cells stably expressing eGFP-tagged FGFR2 WT, Y376C or N550K (green) with an mCherry-tagged ER marker (Sec61–mCh, magenta). The input intensity
range of the FGFR2-Y376C–eGFP image is scaled to 50% for display purposes to prevent saturation of vesicular structures. Vesicular structures are adjacent to
ER in both wild-type and mutant-expressing cells and move unhindered in all conditions. Scale bar: 10 µm. (C) eGFP-tagged FGFR WT and Y376C
receptor and ER dynamics at the cell periphery in the regions indicated by the boxes in B. Scale bar: 1 µm; time is in seconds, yellow dotted line marks cell
periphery. (D) Live-cell spinning disc confocal microscopy of Ishikawa cells stably expressing eGFP-tagged FGFR2 WT or N550K (green) with an mCherry-
tagged Golgi resident protein (mCh–Rab6, magenta). (E) Time-lapse sequence of dynamic behaviour of eGFP-tagged FGFR WT or N550K (green) and Rab6
Golgi dynamics (magenta) from boxed regions in D. White arrowheads in C and E correlate with eGFP vesicles in the time-lapse sequence. Time is in seconds.
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surface (Fig. 6A–C, upper panels). In 3D acini, WT FGFR2
displayed a predominant plasma membrane localization as well as
localization to intracellular puncta (Fig. S5). Similar to what was
observed in 2D, in 3D this intracellular localization was enhanced in
FGFR2 mutants. In contrast to WT acini, and similar to our single-
cell findings, Golgi orientation and polarity was lost in FGFR2
mutant acini as evidenced by the failure of β4-integrin to localize to
the basal surface (Fig. 6A–C, lower panels corresponding to N550K
and Y376C acini). Moreover, we observed differences in
morphology in the acini from cells expressing each of the
mutants. Acini formed from N550K cells exhibited a multi-
lobular phenotype, a structure that consisted of multiple lobules of
smaller acini that we revealed to be connected by creating complete
maximum intensity projections of F-actin z-sections (Fig. 6A, red
and blue dotted outlines). In contrast, Y376C acini grew as larger,
amorphous bulging structures, appearing to be double the size of
control WT acini. This observation was supported by analysis of
acini size (8 day, Fig. 6D; mean size: empty vector 3343 µm2, WT
3447 µm2, N550K 5901 µm2, Y376C 9217 µm2), indicating that in
a 3D environment, the expression of the activating FGFR mutants
increases proliferation in comparison to WT. As we observe a
perturbed Golgi in both mutants, these results suggest that, although
individual mutations can result in different modulation of
downstream molecules, these appear to converge on the common
target of Golgi orientation and polarity.
To test whether the activating mutants had an effect on migration
in a collective context, we generated acini (day 3) and examined their
multicellular dynamics using time-lapse differential interference
contrast microscopy in the presence and absence of FGF10 for 72 h.
To understand the variation of migration and invasion phenotypes
that we observed during time-lapse imaging, acini morphology was
classified into three categories: spherical, lobular/branching and
protrusive/bulging (see key in Fig. 6F). The morphology of empty
vector, WT, Y376C and N550K acini, was then scored in the
Fig. 4. A fragmentedGolgi correlates with an aberrantmigration phenotype in cells expressingmutant FGFR2. (A) Representative images of cells expressing
eGFP-taggedFGFR2WT,N550KandY376C fixedandstained for theGolgimarkerGM130 (white), andDAPIasanuclear stain (cyan). (B)Quantificationof thedegree
of Golgi fragmentation around the nucleus in sub-confluent Ishikawa cell monolayers. The Golgi fragmentation angle α (yellow line in A) was defined as the angle
through thecentreof thenucleus that encompassesallGolgi structures.n=149 (EV), 121 (WT), 227 (N550K), 189 (Y376C).Dataare threebiological repeats combined.
Box-and-whisker plots show the median, first and third quartile (box), and 95% confidence intervals (notches), with whiskers extending to the furthest
observations within ±1.5 times the interquartile range. Dots are individual data points. P-values were calculated with a non-parametric Kruskal–Wallis analysis of
variancewithBonferroni error correction, andare displayed on graph. (C) Scratchwoundhealing assay in Ishikawacells stablyoverexpressingFGFR2WT,N550Kand
Y376C with co-transduced mCherry to allow for high contrast imaging and tracking. Cells were pre-treated with 10 µg/ml Mitomycin C for 1 h, wounded and
serum starved (0.5% FBS) for 2 h. Cells were stimulated with heparin (5 µg/ml; control) or FGF10 (50 µg/ml) in the presence of heparin, in medium with 2% serum.
Dashed lines represent the edge of the wound. (D) Analysis of cell migration rates (relative wound density/time) in control or with FGF10. Relative wound density was
calculated by IncuCyte™ChemotaxisCellMigration Software. Frameswere acquired every 2 h for a 24 h period. Thewound closure ratewas calculated bymeasuring
the slope of the line between t0 and the final time at 24 h. Dots are individual data points. Each box-and-whisker plot represents the median, first and third quartiles
(boxes) and 95% confidence intervals (notches) with whiskers extending to the furthest observations within ±1.5 times the interquartile range (IQR), of three
independent experiments with n=4 biological replicates per condition/experiment. (E) Representative frames from time-lapse data demonstrating aberrant cell
morphology phenotype of mutant cells at wound edges. Outlines of cells are highlighted with a dotted line.
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presence and absence of FGF10 (Fig. 6E). Stimulation with FGF10
resulted in a mild increase in invasive-like protrusions at the matrix-
abutting surface of acini comprising cells expressing WT receptor
(Movie 7), which was not observed in empty vector controls. In
mutant-expressing acini, FGF10 stimulation resulted in increased
invasion into the matrix. Cells expressing N550K preferentially
exhibited more lobular/branching morphology with a slight increase
upon the addition of ligand. This morphology correlated with a
Fig. 5. See next page for legend.
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greater propensity for cells to leave the acini and migrate into the
matrix, both in chains and as individual cells. In contrast, Y376C-
expressing cells tended to undergo a bulging and protrusive type of
growth, bubbling and pushing into the matrix, with an increase in
lobular/branching invasive migration upon the addition of ligand.
These findings suggest that the increased proliferation, and loss of
multicellular polarity in combinationwith an increased propensity to
invade, observed with activating FGFR mutations may play an
important role in the pathology of FGFR-associated endometrial
cancer.
DISCUSSION
Growth factor-driven cell migration is significantly linked to the
dissemination of tumour cells, a process in carcinomas that typically
requires invasion of cells as a cohesive group termed ‘collective
invasion’ (Friedl et al., 2012). Although the spotlight for growth-
factor driven invasion has long been focused on EGFR, relatively
little is known about the role of FGFR, despite the evaluation of
multiple anti-FGFR agents in ongoing phase I and II clinical trials
(Babina and Turner, 2017). The majority of research pertaining to
FGFR-dependent migration has focused on its role in development
and wound healing, where it plays a role in collective migration
(Vitorino and Meyer, 2008). This study examined the molecular
mechanisms underpinningwhy patients diagnosedwith endometrial
cancer are at a greater risk of metastasis if they carry FGFR2-
activating mutations. To accomplish this goal, we used a well-
differentiated cell model of endometrial cancer to study the
molecular mechanisms of two common endometrial cancer
FGFR2-activating mutations, N550K and Y376C. To our
knowledge, our study is the first to connect cancer-associated
point mutations in FGFR2 to the loss of collective cell polarity,
resulting in cancer cell invasion.
RTKs classically localize to and signal from the cell surface;
however, signalling from intracellular membranes is now a rapidly
developing paradigm of cell biology (Murphy et al., 2009). The
importance of compartmentalization of signalling has been
exemplified by Ras and c-Met, whereby signalling from different
subcellular organelle membranes has shown to exhibit altered
temporal signalling dynamics and have different functional
outcomes (Chiu et al., 2002; Aran and Prior, 2013). Although our
studies do not preclude that FGFR2 mutants may go to an as-yet-
unidentified extra endosomal compartment, they do indicate that
they are signalling from an intracellular location. Interestingly, the
extracellular allosteric FGFR inhibitor (SSR128129E) demonstrates
‘biased antagonism’ whereby the inhibitor can block downstream
MAPK signalling but not PLCγ phosphorylation, supporting the
concept that these pathways can be activated from different
subcellular compartments (Herbert et al., 2016). Future studies
will be directed towards understanding the role that mutant receptor
spatio-temporal localization may play in perturbing Golgi structure,
cell polarity and differential signalling.
Our detailed functional assays demonstrate that, in 2D, both
activating mutations result in a perturbation of Golgi integrity and a
loss of directional migration despite having different levels of
receptor activation evident from western blotting. In basal
conditions (10% FBS), N550K shows a significant increase in
receptor phosphorylation in addition to higher FRS2α and PLCγ
activation than Y376C andWT, yet greater migration is observed for
Y376C. Despite these differences, both mutations show a loss of
directional migration in response to FGF10. Similarly, in the 2D
proliferation assays, N550K showed less proliferation than Y376C
despite higher constitutive receptor phosphorylation. Analysis of
FRS2α and PLCγ phosphorylation over time following stimulation
with FGF10 (Fig. 2) showed a greater persistence of signalling
downstream for Y376C compared to N550K, suggesting that the
enhanced phenotypic effects seen with Y376C could be the result of
changes in temporal signalling downstream of these mutations. This
is further supported by our finding that Y376C exhibits a decrease in
FGF10-mediated receptor internalization dynamics in comparison
to N550K andWT. Our 3D proliferation assays demonstrate that both
mutations lead to increased proliferation as evidenced by increased
acini size but result in strikingly different acini morphologies,
suggesting that the differences we observe in signalling may be
enhanced in an environment that better recapitulates the epithelial
structure of the endometrium. This is supported by our observed
differences in their modes of invasion into the matrix, where a more
branching invasive phenotype was observed in the N550K acini,
compared to the bulging or pushing into the matrix we more
frequently observe in Y376C acini. These data suggest that although
both FGFR2 mutations increase proliferation and invasion in
endometrial cancer cells, there are significant differences in
adaptor and effector signalling molecules utilized by these two
different activating mutations. These differences will be investigated
in the future with detailed phospho-proteomics.
This study highlights the importance of performing functional
assays using 3D models to better understand cancer-associated
mutations. These studies revealed a loss of apico-basal polarity in
both activating mutants, an important step during the progression of
cancer (Muthuswamy and Xue, 2012) and one associated with
increased metastatic capacity. Interestingly, Ishikawa cells form
lumen-containing, polarized acini, even though they lack expression
of the key apico-basal polarity proteins Par3 and PTEN (Weigelt
et al., 2013; Williams et al., 2017). Despite both mutants causing a
loss of apico-basal polarity and an absence of basement membrane,
N550K-expressing cells tended to be more invasive while Y376C-
expressing cells instead preferentially proliferated, pushing against
Fig. 5. FGFRmutant cells do notmigrate persistently during FGF-induced
chemotaxis. (A) Spinning disc confocal time-lapse sequence of cells co-
expressing mCherry (magenta) with EV-eGFP, eGFP-tagged FGFR WT or
mutant (N550K, Y376C) (green), stimulated with a chemotactic gradient (low–
high) of heparin alone (5 µg/ml, control) or heparin plus FGF10 (50 ng/ml), in
medium with 2% serum. Hoechst 33342 was used to identify cell nuclei (blue).
Cell outlines displayed are traces outlined every 50 min for 8 h. The initial frame
(t0) is outlined in green and the final frame is outlined in magenta; remaining
time points are opaque. Cell migration paths are outlined in blue (dotted line).
Plots of representative cell migration paths in control (heparin) and FGF-
treated cells (50 ng/ml). The 30 longest paths from each condition are
displayed. Cells were tracked in Imaris (Bitplane) using the ‘ImarisTrack’
function using the analysis criteria outlined in the Materials and Methods.
Migration paths were normalized to the starting position. Representative data
set of three independent experiments. Analysis of cell migration from three
experiments, n=90 cells per condition. (B) Total track length (µm), (C) cell
displacement (shortest distance between t0 and the final frame; µm),
(D) persistence index (ratio of cell displacement to total track length) and
(E) cell migration speed (µm/min). The box-and-whisker plots show median,
first and third quartiles (boxes) and 95% confidence intervals (notches) with
whiskers extending to the furthest observations within ±1.5 times the
interquartile range (IQR). Dots are individual data points. Black dots are
outliers >1.5 and <3 the IQR, grey dots are outliers >3 IQR. P-values were
calculated with a non-parametric Kruskal–Wallis analysis of variance with
Bonferroni error correction. (F) Spinning disc confocal microscopy of Ishikawa
cells co-expressing either a wild-type (WT) or activing mutant (N550K)
FGFR2-eGFP (magenta) with mCherry–Lifeact (black), stimulated with FGF10
(50 ng/ml). Time is in min. (G) Higher magnification regions of the advancing
cell edge of cells in F. (H) Kymograph of actin dynamics in WT and N550K
expressing cells. Time scale is in min.
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the ECM, although switching to an invasive phenotype upon the
addition of ligand.
The loss of multicellular polarity and resulting invasive
phenotype we observe in our FGFR-activating mutants can be
linked to our novel observation connecting FGFR2 mutant
expression to a perturbation of Golgi morphology. Orientation of
the Golgi towards the leading edge of a migrating cell is thought to
elicit efficient delivery of membrane components and signalling
Fig. 6. Effects of FGFR activating mutations on endometrial acinar morphogenesis. (A) Maximum intensity projections of four, 2 µm spinning disc confocal
optical sections of Ishikawa acini grown in growth factor-reduced Matrigel™ overlay assay. Ishikawa cells expressing empty vector (EV-eGFP), eGFP-tagged
(green) wild-type, or mutant N550K or Y376C FGFR grown for 8 days to form acini. Acini are co-stained for DAPI (white) and for F-actin (phalloidin) (A), the
Golgi (GM130) (B) or the basement membrane (β4 integrin; magenta) (C). Blue and red dashed line indicate the outline of the complete maximum intensity
volume reconstruction. (D) Quantification of 8-day acinus size. Box-and-whisker plots show median, first and third quartile (box), and 95% confidence
intervals (notches) with whiskers extending to the furthest observations within ±1.5 times the interquartile range. Dots are individual data points. P-values were
calculated by non-parametric Kruskal–Wallis analysis of variancewith Dunn’s multiple comparisons test correction and are displayed on graph. (E) Quantification
of acinus morphology phenotypes observed from time-lapse imaging (72 h) of cells expressing empty vector (EV-eGFP), eGFP-tagged wild-type or mutant
(N550K, Y376C) FGFR, stimulated with either heparin alone or heparin plus FGF10 in 2% serum. Acinus phenotypes were categorized as spherical,
bulging/lobular or protrusive/bulging. All three phenotypes were observed in each condition at different ratios. Analysis (mean±s.e.m.) is from three combined
experiments; n values are displayed on graph. (F) Acini morphology key corresponding to graph E. See Movie 7.
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required for motility. In addition to a loss of Golgi polarization, we
observed that mutant cells failed to reorient their intracellular FGFR
pool towards the leading edge, which correlated with a lack of
productive migration. Interestingly, FGF signalling has recently
been linked to Golgi orientation during craniofacial development
(Li et al., 2013). Ectopic activation of FGFR2 signalling in cranial
neural crest cells with FGF8 or FGFR2C278F and detailed
quantification of the Golgi angles 72 h later, showed a more
randomized Golgi distribution indicative of altered cell polarity
compared to normal embryos. In further support of our findings,
activation of inducible FGFR1 and FGFR2 with the dimerizing
agents AP20187 has been shown to lead to a loss of apico-basal
polarity in a model of primary mammary epithelial cell 3D culture
(Xian et al., 2007), although changes to the Golgi were not
examined in this model.
From a clinical perspective, endometrial cancer patients with
early disease (stage I/II) that carry somatic activating FGFR2
mutations show an increased risk of disease recurrence (Byron et al.,
2012; Jeske et al., 2017). Decreased cancer-specific survival is also
seen in endometrial cancer patients with somatic FGFR2 mutations,
irrespective of stage (Jeske et al., 2017). We propose that the loss of
multicellular polarity and increased invasion we have observed in
Ishikawa cells carrying two common hotspot mutations in FGFR2
results in an increase in metastasis from the primary site, likely
increasing the risk for recurrent disease despite surgical resection of
the primary tumour. This study performed within an appropriate
endometrial cancer context also has additional translational
implications. Specifically, the increased localization of mutant
receptors to a perinuclear pool suggests that therapeutic agents
targeting cell surface receptors such as neutralizing antibodies
(Bai et al., 2010) or the novel extracellular allosteric inhibitors
SSR128129E or Alofanib (Herbert et al., 2016; Tsimafeyeu et al.,
2016) will not be as effective as small molecule kinase inhibitors
that can block signalling independent of receptor localization.
MATERIALS AND METHODS
Cell culture
HEK-293FT (Invitrogen) cells were cultured in DMEM (Gibco), 10%
fetal bovine serum (FBS, Gibco), 100 µg/ml penicillin, 100 µg/ml
streptomycin and 0.1 mM MEM non-essential amino acids. HEK-293FT
cells were supplemented with 2 mM L-glutamine and 0.5 mg/ml Geneticin/
G418 (Invitrogen, 10131035). pLex307-transduced Ishikawa cells were
maintained in 2.5 µg/ml puromycin dihydrochloride (Invitrogen, A11138-
03), whereas pLenti6-transduced cells were maintained in 5 µg/ml
Blasticidin (Invitrogen, 461120). Cell lines were authenticated by STR
profiling (QIMR Berghofer Medical Research Institute).
DNA constructs and lentiviral vectors
FGFR2WT–eGFP and mutant FGFR2N550K–eGFP and Y376C–eGFP were
made by sub-cloning the epithelial b isoform of FGFR2 (a gift from Zamal
Ahmed and John E. Ladbury, M.D. Anderson Cancer Center, Houston, TX)
in frame with the eGFP tag, including a seven amino acid linker region, in
the entry vector pENTR1A-GFP-N2 (Addgene plasmid #19364, deposited
by Eric Campeau; Campeau et al., 2009), then recombined into pLex307
(Addgene plasmid #41392 deposited by David Root, MIT, Cambridge,
MA), using LR clonase (Invitrogen 11791-100) with slight modifications to
the manufacturer’s instructions as previously described (Stehbens et al.,
2012). pLenti-LifeAct mCherry was a generous gift from Diane Barber
(UCSF, San Francisco, CA), pLenti6 pmRab6-mCherry, pLenti6
pmCherry-Sec61 Lentiviral particles were produced in HEK293FT cells
using packaging plasmids as previously described (Byron et al., 2013;
Stehbens et al., 2012, 2014). To generate stable fluorescent protein-
expressing Ishikawa cell lines, cells were seeded to be 70% confluent on the
day of infection in a 60 mm dish. Cells were incubated with lentiviral
particles for 16 h with 5 µg/ml polybrene (Millipore TR-1003) before
selection in 2.5 µg/ml puromycin for 2 weeks. Homogenous low expression
levels were selected for by performing FACS and analysed by live-cell
imaging and western blot analysis of eGFP. For scratch wound and
migration assays, cells expressing eGFP-tagged WT, N550K or Y376C
FGFR, or eGFP vector alone, were infected with empty vector pLex307
mCherry and selected for by fluorescence-activated cell sorting to enable
high-contrast visualization and quantification.
Antibodies, immunofluorescence and immunoblotting
Primary antibodies used for immunofluorescence and immunoblotting,
including specific dilutions, are listed in Table S1. All secondary
fluorescently labelled antibodies were highly cross-absorbed secondary
antibodies from Jackson ImmunoResearch. For 2D immunofluorescence,
samples were fixed with 4% paraformaldehyde (PFA; EM grade, 15710,
Electron Microscopy Services) in BRB80 buffer (80 mMK-PIPES, pH 6.8,
1 mM MgCl2, 1 mM EGTA) for 20 min at room temperature, washed three
times with PBS and permeabilized with 0.25% Triton X-100 in PBS for
5 min. Samples were rinsed three to five times in blocking buffer (2% BSA,
0.1% Triton X-100, 0.1% NaN3 in PBS). Samples were incubated with
primary antibodies diluted in blocking buffer for 1 h at room temperature.
Samples were rinsed three to five times in blocking buffer for 5–10 min each
before incubating in secondary antibodies (1:500) for 45 min at room
temperature. Secondary antibodies and phalloidin were diluted in blocking
buffer. Samples were rinsed three to five times in PBS, for 5–10 min
each, then mounted in Mowiol mounting medium {0.1 M Tris-HCl pH 8.5,
25% glycerol, 10% Mowiol 4-88; 475904, Calbiochem, 2% DABCO
[1,4-Diazabicyclo(2.2.2)octane, D2522, Sigma]}. For 3D assays
immunofluorescence was analysed as described previously (O’Brien
et al., 2006). In brief, samples were washed two times quickly with PBS+
(PBS supplemented with 0.9 mM CaCl2 and 0.5 mM MgCl2) at room
temperature before fixation with 4% PFA diluted in BRB80 for 20 min at
room temperature. Samples were washed twice with PBS+ for 5–10 min
each before permeabilizing with 0.5% Triton X-100, PBS for 10 min at 4°C,
then placed in PFS blocking solution (PBS+, 0.7% fish skin gelatin, 10%
saponin, 0.02% NaN3) for 30–60 min at room temperature, with gentle
shaking. Primary antibodies were diluted in PFS and incubated for 2 h at
room temperature with gentle rocking. Samples were then washed three
times for 5 min each in PFS with gentle rocking at room temperature.
Samples were incubated with secondary antibody diluted in PFS for 60 min
at room temperature with gentle rocking before washing three times for
5 min each in PFS. Samples were stored at 4°C in PBS+, 0.02% NaN3 and
0.1% n-propyl gallate anti-fade.
For immunoblotting, cells were washed once with ice-cold PBS before
lysis in ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1% sodium deoxycholate,
0.1% sodium dodecyl sulfate and protease inhibitors) containing
phosphatase inhibitors (50 mM NaF, 1 mM NaVO4 and 10 mM sodium
pyrophosphate) for 5 min on ice, scraped off the tissue culture dish,
transferred to an Eppendorf tube, and incubated on ice for an additional
5 min. Cell lysates were sonicated at 50% amplitude, three times at 2 s
intervals, with 30 s rest on ice between intervals. Cell lysates were then
centrifuged at 21,130 g for 15 min and supernatants transferred to new tubes
for either a BCA assay or to one containing SDS-PAGE sample buffer.
Samples were heated to 100°C for 5 min, and centrifuged prior to loading.
20 µg of protein was loaded per lane onto a 5–15% gradient Tris-glycine gel.
Proteins were separated by SDS-PAGE. Proteins were transferred by wet
transfer for 2 h at 110 V onto nitrocellulose (Bio-Rad Mini Trans Blot
Apparatus). Membranes were incubated for 1 h in blocking buffer (5% non-
fat dry milk, TBS and 0.1% Tween-20) at 4°C. Primary antibodies were
diluted (see Table S1 for dilutions) in 3% BSA blocking buffer and
incubated with membrane for 2 h at room temperature on an orbital shaker,
then washed five times in TBSwith 0.1% Tween-20. Secondary horseradish
peroxidase (HRP) conjugated antibodies were diluted 1:10,000 in 5% BSA-
containing blocking buffer and incubated with membranes at room
temperature for 1 h, washed ten times in TBS with 0.1% Tween-20, and
rinsed once in TBS prior to incubation with ECL (WBLUF0100, Merck
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Millipore). Membranes were imaged using a Quantum ST4 documentation
system (Vilber Lourmat), cropped in Adobe Photoshop CS6 and assembled
in Adobe Illustrator CS6. LUTs were adjusted linearly to enable comparison
of protein of interest to loading controls.
Microscopy, image processing and data analysis
Scratch wound assays were imaged on an IncuCyte® ZOOM Live-Cell
Analysis System (ESSENBioScience). Live-cell digital interference contrast
imaging was performed on an environmentally controlled Olympus CellR
inverted IX83 microscope, equipped with a Hamamatsu Orca Flash 2.8 CCD
camera, controlled by Olympus Xcellence software. Epifluorescence images
were acquired on an Olympus BX63 epifluorescence microscope controlled
using the CellSense Dimension 1.11 software (Olympus). SDC live-cell
imaging was performed on an environmentally controlled Nikon Ti inverted
microscope with a Borealis-modified Yokogawa CSU-X1 confocal head
(Spectral Applied Research) and equipped with a Clara cooled scientific
grade interline charge-coupled device (CCD) camera (Andor). Intracellular
fluorescent protein-tagged protein dynamics were imaged at 37°C using
either a ×60 or ×100 1.49 numerical aperture CFI apochromat TIRFobjective
(Nikon). TIRF images were acquired on the same TI inverted microscope
stand (Nikon) equipped with a motorized TIRF illuminator (Nikon), an
Evolve Delta electron-multiplying CCD camera (Photometrics) and a ×100
1.49 numerical aperture CFI Apochromat TIRF objective (Nikon) using ×1.5
intermediate magnification. Emission wavelengths were separated using a
filter wheel (Sutter) mounted between microscope and electron-multiplying
CCD camera. The details of this system are published elsewhere (Li et al.,
2013). SDC microscope hardware was controlled by NIS Elements software
(Nikon), and image processing and analysis was performed in NIS Elements.
Generally, for display purposes, image contrast was linearly adjusted on the
14- or 16-bit raw data, images were low-pass filtered in NIS Elements (Detail
level: 2), and processed with an unsharp mask filter (Power: 0.5; Area: 7).
Figureswere assembled usingAdobe Photoshop and IllustratorCS5 (Adobe).
Videos were assembled in Quicktime Pro (Apple). For live-cell microscopy,
the growth medium was supplemented with 20 mM HEPES pH 7.5 (Gibco,
15630-080), and the glass-bottom dishes (Cellvis 4-Chamber 35 mm glass
bottom dish with 20 mm microwell, #1.5 cover glass, D35C4-20-1.5-N) or
eight-well chambers (IBIDI 8-well glass bottom: #1.5 cover glass, 80827)
were sealed with vacuum grease to prevent medium evaporation. Eight-well
chamber slides were fitted with a glass lid for DIC imaging (IBIDI DIC Lid
for µ-Slides, 80055). Black/magenta image overlays were generated as
described previously (Stehbens et al., 2014).
Ligand internalization assays
Cells expressing wild-type or mutant eGFP-tagged FGFR2b were plated
onto glass-bottom dishes (Cellvis 4-Chamber 35 mm Glass Bottom Dish
with 20 mm microwell, #1.5 cover glass, D35C4-20-1.5-N) to achieve 30%
confluence the following day. Samples were rinsed three times in DMEM
containing 0.5% FBS then starved at 37°C for 2 h. Starved cells were
imaged prior to being stimulated with FGF10 (50 ng/ml) and heparin (5 µg/
ml) in 2% FBS for 60 min. Frames were acquired every 3 min.
Cell proliferation assays
Sulforhodamine B (SRB) cell proliferation was performed as previously
published (Vichai and Kirtikara, 2006), with the following modifications.
Cells were seeded at 2500 cells per well in a 96-well plate, and cellular
proliferation assessed over 4 days in medium containing 0.5% FBS and 5 µg/
ml heparin, in the absence and presence of 50 ng/ml FGF-10. 100%methanol
was used to fix cells, and absorbance was read at 564 nm (Multiskan Go,
Thermo Fisher Scientific). All absorbance values were corrected to a
medium-only well and normalized to the values at day 0.
Scratch wound assay
Cell scratch migration assays were carried out on the InCucyte Zoom (Essen
BioScience) machine. Briefly, cells were seeded into image lock plates
(Essen Bioscience) and wounded using the wound maker (Essen
Bioscience), then starved in 0.5% FBS medium for 2 h before stimulation
with 50 ng/ml FGF10 (R&D Systems FGF10 345-FG or Ray Biotech 213-
10087-2AF) and 5 µg/ml heparin (Sigma-Aldrich, 3149) in 2% FBS-
supplemented medium. In all scratch wound migration assays, cells were
treated with 10 µg/ml Mitomycin C (Sigma, M4287) for 1 h to inhibit
proliferation. Wound closure was captured every 2 h for 24 h and analysed
using IncuCyte Zoom software (Essen Bioscience). Relative wound density
(RWD) was plotted against time. The rate of wound closure was calculated
as the slope of this curve.
Chemokinesis migration assay
Chemokinesis migration assays were carried out on a custom-designed
environmentally controlled SDC microscope as described previously
(Turner and Grose, 2010). Cells were seeded onto glass bottom chamber
slides and starved for 2 h in 0.5% FBS medium before stimulating with
50 ng/ml FGF10 and 5 µg/ml heparin in medium containing 2% FBS.
Movies spanned 8 h, with frames captured every 5 min. Cell tracking was
completed using Imaris software (Bitplane).
Chemotaxis migration assay
Random migration assays were carried out on a custom-designed
environmentally controlled SDC microscope as described previously
(Stehbens et al., 2012). To assess directional migration at a single-cell level,
10,000 cells were seeded onto one side of glass bottom chamber slides (IBIDI,
80827). Cells were allowed to adhere overnight while growing at an inclined
angle of 45°. Cells were then washed twice with PBS and starved for 2 h in
0.5% FBS medium. 50 µl of growth factor-reduced Matrigel™ (GFR-MG;
Corning, 354230, lot# 5313010) was then mixed with 50 ng/ml FGF-10 and
5 µg/ml heparin and allowed to solidify on the chamber wall opposite to
adherent cells. Before imaging, medium was replaced with fresh 2% FBS-
supplemented medium to allow the creation of a chemotactic gradient
originating from the solidified Matrigel™.
Temporal signalling assay
Cells were grown to 50% confluence before being starved overnight in
DMEM (Gibco, see above) containing 0.5% FBS. Following starvation,
cells were stimulated with FGF10 (50 ng/ml) and heparin (5 µg/ml). At the
indicated time intervals, cells were washed once in ice-cold PBS before
lysates were collected in RIPA buffer containing protease inhibitors (see the
Antibodies, immunofluorescence and immunoblotting section for details).
Cell surface biotinylation assay
Biotinylation experiments were performed as described previously (Adams
et al., 2015). In brief, Ishikawa cells were either grown in 10% FBSmedium
or starved in 0.5% FBS medium for 2 h before being washed with PBS and
biotinylated (Pierce, 21331) for 1 h at 4°C. Following biotinylation, cells
were washed with PBS and lysed in RIPA buffer containing protease
inhibitors (see above) and disrupted by sonication on ice. After removal of
cellular debris by centrifugation (18,400 g for 10 min at 4°C), lysates were
incubated with streptavidin beads (Cell Signaling Technology, 5947)
overnight at 4°C.
3D acinus assays
Acini were formed as described previously (O’Brien et al., 2006). In brief,
GFR-MG (Corning, 354230, lot# 5313010) was thawed on ice for 30 min.
20 µl of 100% GFR-MGwas spread evenly across each well of a pre-chilled
eight-well glass bottom chamber slide, placed on top of an inverted 10 cm
dish over ice, using a chilled, flat p200 tip. The slide was then placed at 37°C
and the GFR-MG allowed to set for 10–30 min while cell dilutions were
prepared. A solution of 4% GFR-MG was prepared by diluting 100% GFR-
MG with complete medium. The solution of detached cells was passed
through a BD cell strainer (Corning, 352340), to ensure cells were fully
separated and suspended, before being diluted to 20,000 cells/ml, then
mixed 1:1 with the 4% GFR-MG solution. 300 µl of the cell–GFR-MG
solution was added to each well of an eight-well chamber slide. The day of
plating is considered day zero. Medium was changed 5 days after plating.
For live-cell DIC time lapse imaging, day 3 acini were gently washed with
0.5% FBS three times, then serum starved for 120 min in 0.5% FBS. Acini
were then stimulated with 50 ng/ml FGF10 (Ray Biotech, 213-10087-2AF)
and 5 µg/ml heparin (Sigma-Aldrich, 3149) in 2% FBS-supplemented
medium, or with heparin alone as a control. Acini were imaged for 72–96 h.
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Acini morphology was classified as either, spherical, lobular/branching or
protrusive/bulging, which were defined by growth characteristics observed
over time and are displayed in Fig. 6F (morphology key). Spherical was
defined as acini that were round, characteristic of polarized acini, lobular/
branching were defined as acini where lobes would protrude from multiple
sides of the acini, which would often result in branching of cells into the
matrix and protrusive/bulging were defined as acini that appeared to push
into the matrix with central bulging, consistent with non-polarized central
divisions. Acini size (area) measurement was performed using NIS
Elements AR ‘area’ tool of maximum intensity projection images from
z-stacks of 8 day acini.
Vesicle size and dynamics
Vesicle size was measured using NIS Elements AR Version 5.01 (Nikon)
using the General Analysis 3 Application. Two binary object masks were
created by thresholding for object size and intensity to detect both small and
large objects on images of live cells. Vesicle dynamics were measured using
the ‘binary tracking’ tool on timelapse images. The mean square
displacement of object tracks were calculated as a sum of squared
distances from the beginning of the track.
Receptor surface localization analysis
TIRF images were acquired on live-cells plated on glass bottom
dishes (Cellvis 4-Chamber 35 mm Glass Bottom Dish with 20 mm
microwell, #1.5 cover glass, D35C4-20-1.5-N). 9×6.5 µm2 regions of
interest (ROIs) were placed within 1–10 µm along the free edge of the cells.
All ROIs were background corrected (identical ROI in cell free area). Cell
surface labelling was performed by performing immunofluorescence on
eGFP–FGFR2b WT and mutant-expressing cells in non-permeabilized
conditions (no detergents) using anN-terminal FGFR2 antibody. Cell outline
ROIs were generated using the Bezier ROI tool in NIS elements. Background
corrected, surface fluorescence intensity values (antibody fluorescence,
594 nm) were expressed as a ratio of total (eGFP fluorescence, 488 nm).
Golgi complex angle measurement
Golgi angle analysis were carried out using NIS-Elements AR Version 4.40
(Nikon) using the free angle measurement tool as described previously
(Xian et al., 2007).
Scratch wound assay analysis
Scratch wound assay measurements are displayed as percentage (%) relative
wound density (RWD). RWDwas measured using InCucyte Zoom software
and is a measurement of cell density of the wound area relative to cell
density outside of the wound area over time. The RWD measurement is
normalized for changes in cell density caused by proliferation and/or
pharmacological treatment effects.
Cell migration analysis
For quantification, track lengths greater than 50% of the movie duration
were selectively chosen while tracks 20 µm from the border were eliminated
to exclude tracks that deviated out of frame. Random migration was
defined by measuring the total change in distance (µm) and direction from
the centre of each cell. Spider plots were created by mapping individual cell
tracks and normalizing each point to 0,0 (x,y) to determine relative positions
using:
Relative x or y position ðmmÞ ¼ x or y positionTime Initial
 x or y positionTime current :
Total path length (t) was calculated through:
Xx;y Final
i¼x;y Initial
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðx2Þ þ ðy2Þ
p
:
Total displacement (d ) was calculated using:
DisplacementðdÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðx2Þ þ ðy2Þ
p
:
Persistence (m) was calculated:
Persistenceð pÞ ¼ d
t
:
Software and statistical analysis
Microsoft Excel was used to perform statistical tests, graphing and the
generation of spider plots. For statistical tests, the plug-ins Analyse-IT in
conjunction with Kutools for Microscoft Excel or and Prism 7 (Graphpad)
were used. Data sets were tested for normality using a Shaprio–Wilk test. A
non-parametric, Kruskal–Wallis one-way analysis of variance with a
Bonferroni correction or Dunn’s multiple comparisons test was chosen to
assess significance between independent samples (see figure legends).
A significance value of 0.05 was taken as a cut-off for significance.
Statistical summary for all data can be found in Table S2. Adobe Illustrator
and Photoshop Creative Cloud 2015 were used to generate figures in this
paper.
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